Vimal Datt

Vimal Datt

Auto-generated profile, based on publicly available information

Vimal Datt

Department of Pharmaceutical Chemistry, Noida Institute of Engineering and Technology (Pharmacy Institute), 19, Knowledge Park II, Greater Noida, U.P. - 201306, India

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2022 in Letters in Drug Design & Discovery
Verified
Journal Article
Closed access
PDF file
KSKm Shabana
Km Shabana
SSSalahuddin Salahuddin
Salahuddin Salahuddin
AMAVIJIT MAZUMDER
AVIJIT MAZUMDER
Rajnish KumarRajnish Kumar
Rajnish Kumar
VDVimal Datt
Vimal Datt
MSMohammad Sarafroz
Mohammad Sarafroz
Background: Benzimidazole (Benz-fused bicyclic ring system) is the most versatile class of heterocyclic compounds due to its numerous applications in industrial and synthetic organic chemistry because of its many biological actions. Benzimidazole analogs have been used to discover various medical problems, such as cancer, bacterial infections, fungi infections, etc. Researchers are studying nitrogencontaining hybrid heterocyclic compounds because they provide a broad range of therapeutic potential and have minimal side effects. Objective: The current literature review emphasizes recent developments in the design of new benzimidazole derivatives as possible anticancer agents with their relationship between structure and activity, which will give insight into the future design of more active benzimidazole molecules. Results: The present review consists of synthetic protocols for the synthesis of benzimidazole derivatives along with their pharmacological potentials and structure-activity relationship in correlation with synthetic molecules to provide a depth view of the work done on benzimidazole. Conclusion: It would be significant for further research in developing better drug molecules representing a potent derivative of medicinal agents.

1 November 2023 in Current Organic Synthesis
Verified
Journal Article
Closed access
PDF file
ASAbhishek Shankar Sharma
Abhishek Shankar Sharma
SSSalahuddin Salahuddin
Salahuddin Salahuddin
AMAVIJIT MAZUMDER
AVIJIT MAZUMDER
Rajnish KumarRajnish Kumar
Rajnish Kumar
VDVimal Datt
Vimal Datt
MOHAMED JAWED AHSANMOHAMED JAWED AHSAN
MOHAMED JAWED AHSAN
Due to their diverse applications in industrial and synthetic organic chemistry, quinoline and 1,3,4-oxadiazole have become important heterocyclic compounds. Quinoline and 1,3,4- oxadiazole compounds have been developed for various medical conditions such as anti-cancer, anti-bacterial, anti-fungal, antimalarial, antioxidants, anti-HIV, anticonvulsant, antiviral, etc. The current review includes synthetic protocols for biologically active 1,3,4-oxadiazole incorporating quinoline hybrids with their structure-activity relationship to explore work (Mainly from 2010 to 2021) based on 1,3,4-oxadiazole-quinoline hybrids to the medicinal chemist for further research in the development of the molecule.

1 October 2023 in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
STSonakshi Tyagi
Sonakshi Tyagi
SSSalahuddin Salahuddin
Salahuddin Salahuddin
AMAVIJIT MAZUMDER
AVIJIT MAZUMDER
Rajnish KumarRajnish Kumar
Rajnish Kumar
VDVimal Datt
Vimal Datt
MOHAMED JAWED AHSANMOHAMED JAWED AHSAN
MOHAMED JAWED AHSAN
Quinoline has recently become an important heterocyclic molecule due to its numerous industrial and synthetic organic chemistry applications. Quinoline derivatives have been used in clinical trials for a variety of medical conditions that causes cancer. The present literature study is composed of recent progress (mainly from 2010 to the present) in the production of novel quinoline derivatives as potential anti-cancer agents, as well as their structure-activity relationship, which will provide insight into the development of more active quinoline hybrids in the future. The present review comprises the synthetic protocols of biologically active Quinoline analogs with their structure-activity relationship studies as anti-cancer agents, which provide depth view of work done on quinoline derivatives to the medicinal chemist for future research.

7 February 2023 in Letters in Drug Design & Discovery
Verified
Journal Article
Closed access
PDF file
VDVimal Datt
Vimal Datt
SSSalahuddin Salahuddin
Salahuddin Salahuddin
AMAVIJIT MAZUMDER
AVIJIT MAZUMDER
Rajnish KumarRajnish Kumar
Rajnish Kumar
HSHimanshu Singh
Himanshu Singh
MOHAMED JAWED AHSANMOHAMED JAWED AHSAN
MOHAMED JAWED AHSAN
Heterocyclic compounds are fundamental building blocks for developing novel bioactive compounds. Due to their extensive uses in both industrial and synthetic organic chemistry, quinoline and benzimidazole have recently become important heterocycles. Clinical trials have investigated quinoline and benzimidazole analogues to treat a variety of illnesses, including cancer, bacterial and fungal infection, DNA damage, etc. Medicinal chemists are paying attention to nitrogen-containing hybrid heterocyclic compounds that have a wide range of therapeutical potential with lesser adverse effects. Many efforts have been made to find new and more efficient ways to synthesize these molecules. However, microbial resistance is becoming a major threat to the scientific community; hence, the necessity for the discovery and development of novel antimicrobial drugs with novel modes of action is becoming highly significant. One strategy to overcome this problem is to produce hybrid molecules by combining two or more bioactive heterocyclic moieties in a single molecular platform. Based on established research data on quinoline- bearing benzimidazole derivatives, it can be concluded that both moieties are used for the synthesis of promising therapeutically active agents. This present review comprises the synthetic approaches of biologically active quinolines containing benzimidazole derivatives with their structure-activity relationship studies to provide an overview of the work done on quinoline derivatives to the medicinal chemist for future research.